[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-356742-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-356742-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","zoledronic-acid-inhibits-the-growth-of-er-positive-breast-cancer-cells-by-inducing-ferroptosis","Zoledronic Acid Inhibits the Growth of ER-Positive Breast Cancer Cells by Inducing Ferroptosis","","Zoledronic acid (ZA), a nitrogen-containing bisphosphonate used clinically for osteoporosis, shows antitumor promise in estrogen receptor-positive (ER+) breast cancer. The study investigates ZA’s nonapoptotic anticancer mechanism and finds that ZA triggers ferroptosis through dual inhibition of SLC7A11 and GPX4. Ferroptosis blockade by Ferrostatin-1 reduces ZA cytotoxicity, while GPX4 inhibition with RSL3 synergistically increases lipid peroxidation and cell death. Mechanistic analyses implicate Hippo-YAP signaling in SLC7A11/GPX4 silencing, establishing metabolic vulnerability and suggesting a strategy to overcome endocrine resistance.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/zoledronic-acid-inhibits-the-growth-of-er-positive-breast-cancer-cells-by-inducing-ferroptosis/356742/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/zoledronic-acid-inhibits-the-growth-of-er-positive-breast-cancer-cells-by-inducing-ferroptosis/356742.png","ImageObject",300,407,{"name":42,"@type":43},"นรินทร์","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-15","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",12,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How does zoledronic acid affect ER+ breast cancer cells in this study?","Question",{"text":63,"@type":64},"Zoledronic acid inhibits growth by inducing ferroptosis in ER+ breast cancer cells through suppression of SLC7A11 and GPX4.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What evidence supports ferroptosis as the underlying death mechanism?",{"text":68,"@type":64},"Inhibiting ferroptosis with Ferrostatin-1 significantly attenuates ZA-induced cytotoxicity, while combining ZA with the GPX4 inhibitor RSL3 further enhances lipid peroxidation and cell death.",{"name":70,"@type":61,"acceptedAnswer":71},"Which signaling pathway is implicated in ZA-induced ferroptosis?",{"text":72,"@type":64},"The study reports that ZA activates the Hippo-YAP signaling pathway, promoting YAP phosphorylation, proteasomal degradation, and cytoplasmic retention that ultimately silences SLC7A11 and GPX4.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},356742,1790158967,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":124,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},2336475104957,"https://ap-avatar.wpscdn.com/avatar/22000c4c6bd8a5076e1?x-image-process=image/resize,m_fixed,w_180,h_180&k=1787554080175789136","Original Article  \nBiomol Ther 34(3), 608-617 (2026)  \nZoledronic Acid Inhibits the Growth of ER-Positive Breast Cancer Cells by Inducing Ferroptosis  \nShaofei Yuan1,†, Dejin Shi2,†, Yiyin Xu2,†, Tao Wu2, Shuifeng Liang2, Dinghao Chen2, Jiayi Wang2, Guang Wu2,* and Jiawei Cao2,*  \n1Department of Medical Oncology, Rui’an People’s Hospital, The Third Affiliated Hospital of Wenzhou Medical University, Wenzhou 325200,  \n2 Wenzhou Key Laboratory of Cancer Pathogenesis and Translation, Key Laboratory of Laboratory Medicine, School of Laboratory Medicine and Life Sciences, Ministry of Education, Wenzhou Medical University, Wenzhou 325035, China  \nAbstract  \nZoledronic acid (ZA), a nitrogen-containing bisphosphonate with established clinical utility in osteoporosis management, exhibits emerging antitumor potential in estrogen receptor-positive breast cancer. However, the molecular mechanisms underlying its nonapoptotic anticancer effects remain poorly characterized. This study revealed that ZA induced ferroptosis in ER+ breast cancer cells through dual suppression of cystine-glutamate antiporter SLC7A11 and glutathione peroxidase 4 (GPX4), key repressorsof ferroptosis. Pharmacological inhibition of ferroptosis using Ferrostatin-1 significantly attenuated ZA-induced cytotoxicity, while combinatorial treatment with the GPX4 inhibitor RSL3 synergistically enhanced lipid peroxidation and cell death. Mechanistically, ZA activated the Hippo-YAP signaling pathway, promoting YAP phosphorylation, proteasomal degradation, and cytoplasmic retention, thereby silencing SLC7A11 and GPX4 . We established a novel metabolic vulnerability in hormone-responsive malignancies. These findings position ZA as a bifunctional ferroptosis inducer in ER+ breast cancer, offering a promising strategy to overcome endocrine resistance.  \nKey Words: ER+ breast cancer, Zoledronic acid, Ferroptosis, SLC7A11  \nINTRODUCTION  \nBreast cancer persists as a major global health challenge, representing the most commonly diagnosed malignancy in women and the fourth leading cause of cancer-related deaths worldwide (Bray et al. , 2024; Vineis and Wild, 2014) . The International Agency for Research on Cancer’s report highlights its epidemiological transition, with over 2.26 million new cases incidence. China bears a disproportionate burden, contributing 24% of global cancer incidence and 30% of cancer mortality, where breast cancer constitutes 18% of worldwide diagnoses and demonstrates the most pronounced mortality increase among common cancers (Cao et al. , 2021) .  \nMolecular subtyping classifies breast cancer into three predominant categories based on receptor expression: estrogen receptor-positive (ER+, 70% prevalence), HER2-en-  \nriched (HER2+), and triple-negative breast cancer (TNBC)(Goldhirsch et al. , 2011) . While endocrine therapies such as tamoxifen remain the first-line treatment for ER+ tumors due to their estrogen-dependent proliferation characteristics, approximately 50% of patients eventually develop therapeutic resistance (Nakao et al. , 2018; Patel and Bihani, 2018) . This clinical reality underscores the imperative to develop innovative treatment strategies.  \nZoledronic Acid (ZA), a nitrogen-containing bisphosphonate, clinically approved for osteoporosis treatment through osteoclast inhibition (Black et al. , 2007), has recently demonstrated antineoplastic properties beyond its conventional application. Emerging evidence suggests its ZA’s dual functionality in oncology, where it not only suppresses tumor proliferation but also induces programmed cell death. Notably, preclinical studies have established its efficacy against multiple  \n Open Access  [https://doi.org/10.4062/biomolther.2025.132](https://doi.org/10.4062/biomolther.2025.132)  \nThis is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ([http://creativecommons.org/licens](http://creativecommons.org/licens)es/by-nc/4.0/) which permits unrest","cbCaihbYuQnLudDX","https://ap.wps.com/l/cbCaihbYuQnLudDX","pdf",1446439,"English","# Abstract\n# Introduction\n## Background and clinical challenge\n## Molecular subtyping and endocrine resistance\n## Zoledronic acid and emerging antitumor roles\n# Ferroptosis as a therapeutic target\n## Characteristics and regulatory axes","[{\"question\":\"How does zoledronic acid affect ER+ breast cancer cells in this study?\",\"answer\":\"Zoledronic acid inhibits growth by inducing ferroptosis in ER+ breast cancer cells through suppression of SLC7A11 and GPX4.\"},{\"question\":\"What evidence supports ferroptosis as the underlying death mechanism?\",\"answer\":\"Inhibiting ferroptosis with Ferrostatin-1 significantly attenuates ZA-induced cytotoxicity, while combining ZA with the GPX4 inhibitor RSL3 further enhances lipid peroxidation and cell death.\"},{\"question\":\"Which signaling pathway is implicated in ZA-induced ferroptosis?\",\"answer\":\"The study reports that ZA activates the Hippo-YAP signaling pathway, promoting YAP phosphorylation, proteasomal degradation, and cytoplasmic retention that ultimately silences SLC7A11 and GPX4.\"}]","Zoledronic Acid Inhibits the Growth of ER-Positive Breast Cancer Cells by Inducing Ferroptosis | PDF",1790127062,25,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6494ded821f842db41aea30551ef9815.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f3fb05868457d5825acecdda6b812610.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fc609e5d535e238dd4ace6e3bd106ffd.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c3ead456983d46558dc17f97596b05d0.webp",980,1306]